搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
oncnursingnews
1 天
ESR1 Testing Is Crucial in Second-line HR+, HER2- Metastatic Breast Cancer
During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...
oncnursingnews
4 天
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...
1 天
来凯医药-B现涨超5% 公布LAE002治疗HR+/HER2-乳腺癌Ib期临床优异数据
在2024年欧洲肿瘤内科学会 (ESMO) 大会上,来凯医药公布了其创新产品LAE002联合氟维司群(下简称“联合疗法”),用于标准治疗失败的局部晚期或转移性HR+/HER2-乳腺癌患者Ib期研究的最终数据。在18位 ...
4 天
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early ...
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
Targeted Oncology
2 天
Pelareorep Plus Paclitaxel Extends Survival in HR+/HER2– Breast Cancer
Taken together, the BRACELET-1 results provide compelling support for the potential of pelareorep-based combination therapy ...
Cure Today
6 天
Chemotherapy De-Escalation Associated With Excellent HR+/HER2+ Breast Cancer Survival
Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta ...
Cure Today
3 天
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...
7 天
ESMO 2024丨NATALEE研究新发现:年龄<40岁HR+/HER2-EBC患者因不良反应导致 ...
2024年欧洲肿瘤内科学会(ESMO)年会于9月13日~17日在西班牙巴塞罗那召开。在最新公布的NATALEE研究数据中,一项重要发现揭示了年龄对治疗效果的影响。结果显示,年龄<40岁的HR+/HER2-EBC患者,在接受瑞波西利联合非甾体类芳香化酶 ...
Targeted Oncology
3 天
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈